Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease. Patients with severe asthma make up only a small percentage of the total asthma population but bear a disproportionate amount of financial and clinical burden of the disease. According to our survey results, opportunity exists for therapies that can improve these patients’ quality of life, reduce their exacerbation rates, and/or their use of oral corticosteroids. Novel agents in the pipeline able to demonstrate strong efficacy in these attributes will have substantial influence on physicians’ prescribing decisions for the severe asthma population. However, as highly efficacious therapies become increasingly available for severe asthma and the competition intensifies, convenient delivery and price are also emerging as areas for differentiation for therapies in development.

In Unmet Need | Severe Asthma | US/EU, we provide quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need in this indication. We analyze the commercial opportunities in the treatment of severe asthma and discuss how emerging therapies can capitalize on these opportunities. Additionally, using an adaptive choice-based conjoint analysis, we offer an assessment of trade-offs, across clinical attributes and price, that can impact physicians’ prescribing likelihood and preference shares of select target product profiles.

Questions Answered:

What are the key treatment drivers and goals for severe asthma?
What attributes are most influential, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for severe asthma?
What are the prevailing areas of unmet need and opportunity in severe asthma?
What trade-offs across different clinical attributes and price are acceptable to U.S. pulmonologists and allergists and European pulmonologists for a hypothetical new severe asthma drug?
Markets covered: United States, Germany, United Kingdom

Primary research: Survey of 31 U.S. allergists, 29 U.S. pulmonologists, and 30 European pulmonologists fielded in December 2016.

Key companies: Boehringer Ingelheim, Merck, Roche, Novartis, GlaxoSmithKline, Teva, AstraZeneca, Chiesi, Regeneron, Sanofi, Skye Pharma, Mundi Pharma

Key drugs: Advair/Seretide, Symbicort, Dulera, Foster/Formodual, Breo/Relvar, Flutiform, Spiriva, montelukast, Xolair, Nucala, Cinqair/Cinqaero, benralizumab, tralokinumab, dupilumab


Related Reports

Asthma | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details

Asthma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS F...

View Details